Tilray's 71% European Growth Shifts Focus from US Rescheduling, but Risks Remain

What happened

Tilray Brands reported fiscal first quarter 2027 results showing 71% growth in Europe, a sharp acceleration from the 36% international cannabis growth recorded in Q2 FY26. This supports the company's transformation from a Canadian marijuana producer to a diversified global brand manager across cannabis, beverages, and wellness. The growth likely stems from expanding German and EU medical markets, leveraging Tilray's EU-GMP production and CC Pharma distribution network. However, the article's emphasis on Europe overlooks the still-material US hemp-derived THC ban effective November 2026, which threatens a key beverage growth vector. Overall, the news is incrementally positive but does not eliminate the structural challenges that keep Tilray rated WAIT.

Implication

Investors should view the 71% European growth as evidence that Tilray's international strategy is gaining traction, potentially supporting the bull case if margins and cash flow follow. However, the growth is likely off a small base and may not yet translate into meaningful group profitability; the company still reported an operating loss in Q2 FY26 and relies on non-cash add-backs for adjusted EBITDA. The looming US hemp-derived THC ban could eliminate a previously touted growth segment, and craft beer margins continue to compress. Until Tilray demonstrates sustained positive operating cash flow and clearer regulatory pathways, the stock remains suitable only for tactical trading within the $7–$12 range. The attractive entry remains near $7, and investors should avoid chasing the stock above $12 absent concrete evidence of durable earnings power.

Thesis delta

The new data point reinforces the European growth pillar of the investment thesis but does not alter the core WAIT rating. The master report's base case already assumed double-digit international cannabis growth, and the 71% figure, if sustained, would push toward the bull case. However, the bull case also requires sustained positive free cash flow and regulatory clarity, which remain unproven. Therefore, the thesis delta is minimal: the attractive entry and trim levels stand, with slightly increased attention to European execution as a key monitorable.